| |
| |
|
| Insider
Information: |
Stahl Neil |
| Relationship: |
EVP Research and Devel... |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
50,999 |
|
|
Indirect Shares
|
10,439 |
|
|
| Direct
Value |
$49,823,983 |
|
|
|
Indirect Value
|
$10,198,485 |
|
|
| Total
Shares |
61,438 |
|
|
| Total
Value |
$60,022,468 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
5
|
|
Stock
price went up :
|
0
|
4
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 55.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regeneron Pharmaceuticals Inc |
REGN |
EVP Research and Devel... |
2024-02-26 |
50,999 |
2024-02-26 |
10,439 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
140 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2008-09-30 |
4 |
S |
$21.50 |
$223,119 |
D/D |
(10,317) |
350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2009-07-24 |
4 |
AS |
$20.00 |
$210,740 |
D/D |
(10,537) |
350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Res and Dev Sciences |
• – – |
2009-07-27 |
4 |
AS |
$20.74 |
$558,232 |
D/D |
(26,886) |
350 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-01-09 |
4 |
AS |
$16.88 |
$30,230 |
D/D |
(1,744) |
3,127 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-03 |
4 |
AS |
$15.86 |
$253,760 |
D/D |
(16,000) |
3,127 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-06 |
4 |
AS |
$16.00 |
$137,743 |
D/D |
(8,599) |
3,127 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-11-24 |
4 |
S |
$409.71 |
$901,523 |
D/D |
(2,200) |
3,277 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Therap & Clin Prog Dev |
• – – |
2006-11-01 |
4 |
AS |
$20.00 |
$115,200 |
D/D |
(5,760) |
3,887 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2007-04-23 |
4 |
AS |
$25.41 |
$281,389 |
D/D |
(10,988) |
4,297 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2021-11-29 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,605 |
4,605 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2005-11-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
500 |
4,871 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, PreclinDevel & Biomol Sci |
• – – |
2005-08-05 |
4 |
S |
$9.42 |
$101,098 |
D/D |
(10,677) |
5,371 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-11-21 |
4 |
S |
$415.16 |
$1,289,902 |
D/D |
(3,107) |
5,477 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-12-16 |
4 |
OE |
$30.63 |
$99,976 |
D/D |
3,264 |
6,541 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Therap & Clin Prog Dev |
• – – |
2006-10-31 |
4 |
D |
$20.12 |
$252,526 |
D/D |
(12,551) |
9,647 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Therap & Clin Prog Dev |
• – – |
2006-10-31 |
4 |
AS |
$20.00 |
$834,639 |
D/D |
(41,689) |
9,647 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2003-07-09 |
4 |
AS |
$16.31 |
$34,512 |
D/D |
(2,116) |
10,465 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP, Research & Devel Sciences |
• – – |
2008-09-29 |
4 |
D |
$23.28 |
$341,820 |
D/D |
(14,683) |
10,667 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2019-12-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,625 |
11,380 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-13 |
4 |
AS |
$399.80 |
$4,117,958 |
D/D |
(10,278) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-02-27 |
4 |
AS |
$435.93 |
$4,680,460 |
D/D |
(10,349) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-04-14 |
4 |
AS |
$517.99 |
$2,864,307 |
D/D |
(5,497) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
EVP Research and Development |
• – – |
2020-05-11 |
4 |
S |
$567.50 |
$3,021,289 |
D/D |
(5,305) |
11,380 |
0 |
% |
|
| REGN |
Regeneron Pharmaceuticals... |
officerTitle |
• – – |
2006-02-03 |
4 |
D |
$16.40 |
$252,576 |
D/D |
(15,401) |
11,726 |
|
- |
|
| REGN |
Regeneron Pharmaceuticals... |
SVP Research and Development S |
• – – |
2014-08-11 |
4 |
S |
$339.33 |
$3,959,204 |
D/D |
(11,646) |
13,527 |
0 |
- |
|
140 Records found
|
|
Page 1 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
